Placebos without deception: a randomized controlled trial in irritable bowel syndrome

Area of Science:

• Gastroenterology
• Psychiatry
• Clinical Trials

Background:

• Placebo treatments can influence subjective symptoms, but deception is often considered necessary.
• This study investigated open-label placebo (non-deceptive) vs. no-treatment controls for irritable bowel syndrome (IBS).

Purpose of the Study:

• To determine if open-label placebo is superior to a no-treatment control in managing IBS symptoms.
• To assess the efficacy of non-deceptive placebo administration in a randomized controlled trial.

Main Methods:

• A three-week, two-group randomized controlled trial involving 80 IBS patients (Rome III criteria).
• Participants received either open-label placebo pills or no-treatment with matched patient-provider interactions.
• Primary outcome: IBS Global Improvement Scale (IBS-GIS); Secondary outcomes: IBS Symptom Severity Scale (IBS-SSS), IBS Adequate Relief (IBS-AR), IBS Quality of Life (IBS-QoL).

Main Results:

• Open-label placebo showed significantly higher global improvement scores at both midpoint and endpoint (p<.001, p=.002).
• Significant improvements were observed in symptom severity (IBS-SSS) and adequate relief (IBS-AR) for the placebo group.
• A trend favoring open-label placebo was noted for quality of life (IBS-QoL) at the endpoint (p=.08).

Conclusions:

• Placebos administered without deception may effectively treat IBS.
• Further research is needed to explore the use of informed-consent placebos in IBS and other conditions.